Nkarta reported a net loss of $31.983 million for the first quarter of 2025, with a net loss per share of $0.43. The company's cash balance stood at $351.9 million as of March 31, 2025, which is expected to fund operations into 2029. Research and development expenses were $24.172 million, and general and administrative expenses were $12.392 million.

Nkarta, Inc. reported a net loss of $108.79 million for the year ended December 31, 2024, compared to a net loss of $117.501 million in the previous year. The company's research and development expenses remained relatively stable, while general and administrative expenses decreased. Interest income saw a significant increase.

Nkarta reported a cash balance of $405.3 million as of September 30, 2024, which is expected to fund operations into late 2027. The company is prioritizing the advancement of NKX019 for multiple autoimmune diseases and forgoing further development of NKX019 in lymphoma.

Nkarta reported a cash balance of $450.0 million as of March 31, 2024, bolstered by a recent $240.1 million offering, which is expected to fund operations into late 2027. The company's net loss for the quarter was $29.5 million, or $0.58 per share.

Nkarta's pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101. The company had $250.9 million in cash, cash equivalents and investments as of year-end 2023, which is anticipated to fund operations into 2026.

Nkarta reported its Q3 2023 financial results, highlighting the expansion of its NK cell therapy pipeline into autoimmune disease with NKX019 and the extension of its projected cash runway into 2026 through cost containment measures. The company's pipeline now includes three clinical-stage NK cell therapy programs. First patient in the LN study is expected to be dosed in the first half of 2024.

Nkarta reported a net loss of $33.3 million for the second quarter of 2023, with cash and cash equivalents of $302.2 million as of June 30, 2023. The company's cash runway is anticipated to fund operations into 2025. Clinical updates are planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024.

Nkarta reported cash and cash equivalents of $332.1 million as of March 31, 2023. The company's net loss for the quarter was $30.8 million, or $0.63 per share. Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.

Nkarta reported its Q4 and full year 2022 financial results, highlighting progress in clinical trials for NKX101 and NKX019, and a year-end cash position of $354.9 million expected to fund operations into 2025.

Nkarta reported a net loss of $28.3 million for the third quarter of 2022. As of September 30, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $395.1 million.

Nkarta reported financial results for the second quarter ended June 30, 2022. The company announced positive preliminary data for its co-lead NK cell therapy candidates, NKX101 and NKX019, and raised additional capital for advancing these programs.

Nkarta reported positive preliminary data for NKX101 and NKX019, validating their allogeneic NK cell platform. They have over $400 million in cash and short-term investments following a $230 million public offering in April 2022.

Nkarta reports a net loss of $22.8 million, or $0.69 per basic and diluted share, for the fourth quarter of 2021. As of December 31, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $240.2 million.

Nkarta reported a net loss of $22.4 million for the third quarter of 2021. As of September 30, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $259.8 million. The company expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.

Nkarta reported a net loss of $21.5 million for the second quarter of 2021. As of June 30, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $280.3 million, which is expected to fund operations into at least the second half of 2023.

Nkarta reported a net loss of $19.4 million for the first quarter of 2021 and had cash and cash equivalents of $299.7 million as of March 31, 2021. The company expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.

Nkarta reported a net loss of $13.7 million, or $0.44 per share, for the third quarter of 2020. The company ended the quarter with $330.2 million in cash and cash equivalents.

Nkarta reported financial results for Q2 2020, highlighting the completion of their IPO raising $289.8 million and progress in their NK cell therapy development.